Brain Tumor News!


Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!
Displaying Stories 2550 to 2569 of 7,806
Previous 20           Next 20


11/13/12 Continuous daily sunitinib for recurrent glioblastoma.        

 Unfortunately, another negative study.... using Sunitinib (Sutent) by itself.



11/13/12 A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).        

 Unfortunately - another negative study.. this time with thalidomide.  



11/13/12 Multiple resections for patients with glioblastoma: prolonging survival.        

 This study shows that having multiple surgeries for glioblastomas does improve average survival.  Seems obvious - but in the past some doctors would advise that a 3rd or 4th surgery is a waste of time. This shows that each surgery does extend survival by months.. those moneths can be used to try another treatment.. increasing your chances of beating the tumor.



11/13/12 IBTA E NEWS NOVEMBER 2012        

 This is the newsletter from our friends at the International Brain Tumor Association!



11/13/12 A phase I/II trial of vandetanib for patients with recurrent malignant glioma.        

 This article reports the results of clinical trial of the drug Vandetanib (Caprelsa).  This drug is FDA approved for thyroid cancer and readily avaialble.  It is not approved for brain tumors.

On brain tumors, it did not show good results when used alone.  My thoughts are that this type of treatment needs to either be individualized - used only when you know the patient's tumor overexpressed the targets, or as part of a cocktail where it is combined with other treatments to block multiple pathways at once so the tumor can not evade it.



11/13/12 Health News : Mayo Clinic in Arizona is the First in the Southwest to Offer New Treatment for Recurrent Glioblastoma Brain Tumors        

Although the Novocure NovoTTf-100a device is FDA approved for recurrent glibolastoma, it is not yet available everywhere.  Doctors have to become certified in it's use and the company needs to set up tech support centers in each area served.  For a list of centers that offer it now, go to: http://www.novottftherapy.com/

Disclaimer: Novocure is one of our sponsors!



11/09/12 Houston’s Dr. Marnie Rose Foundation Exceeds $3 Million in Total Donations to MD Anderson’s Brain Cancer Research, Children’s Memorial Hermann Hospital        

 This is from our friends at the Dr. Marnie Rose Foundation. They raised over $3 million to fund brain tumor research!  Excellent job!  For our members in Texas - consider participating in thier Annual Run for the Rose on Sunday, April 14, 2013




11/08/12 Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.        

 This article identifies an interesting link between the development of high blood pressure as a side effect from Avastin or Nexavar and how well it works for Glioblastomas.  Those who developed severe high blood pressure did twice as good as those who did not. Interesting..  too early to depend on it yet - it needs to be confirmed in other studies, but opens the door to new research to figure out WHY this may happen.



11/07/12 Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients - Early Results of a Phase II Trial.        

 This study shows that for elderly GBM patients (65-87 years old), it may be possible to cut the number of radiation treatments in half - to 15 visitis in 3 weeks from 30 visits in 6 weeks, and get about the same results.  Of course, the results either way aren't good enough and it might be best to try a clinical trial of just about anything. However, if you are going to use the standard treatment, saving 15 sessions will make a big difference in quality of life for those 3 weeks.



11/07/12 Polifeprosan 20, 3.85% carmustine slow-release wafer (Gliadel) in malignant glioma: evidence for role in era of standard adjuvant temozolomide.        

 Gliadel wafer is a biodegradeable impant that can be inserted into the resection cavity after removing a brain tumor. It slowly releases chemotherapy directly to the area most likely to have a recurrence.   It was FDA approved about 10 years ago, based on trials run before Temodar was available.   This study updates the results to include people using Temodar and shows about the same results.. a small  improvement in survival time but it had a major  - about 30% -  reduced chance of dying for people who used the Gliadel vs the placebo wafer in the trial.

There were minimal increases in side effects.  Worth considering if you are having a brain tumor surgery - but with one big warning - there are some clinical trials that do not allow people who have used Gliadel.  So it is very important to plan out what you want to do after the surgery. It is a very hard decision if your preferred clinical trial doesn't allow for the use of Gliadel..  you trade an approved treatment with a good chance of helping most patients a little and a few patients a lot (gliadel) for an unproven treatment in the trial that has the chance for a bigger improvement - but has not been shown to be safe or effective yet.



11/01/12 FDA Considering Faster Approval Process for Developers of Drugs for Deadly or Debilitating Diseases        

 This is great news!  Might get us quicker access to the exciting new treatments in the pipeline!



10/29/12 Anti-Alcoholism Drug Helps Fight Deadly Brain Tumor        

  This sounds interesting but it is way too early to get excited about



10/28/12 Landmark Medicare settlement could change lives        

 This is fantastic news.. I hear of many cases where Medicare denies care to brain tumor patients  saying the patient does not have a good chance of improvement.  If you find yourself in this situation, print out this article and give it to your doctor and ask them to fight the decision.



10/22/12 Los Angeles Goes Grey on November 4, 2012        

Excellent event - great cause!  Participate if you can!



10/11/12 UC Irvine opens clinical trial of novel treatment for brain cancer        

  This is one of my favorite clincial trials (it is being done all over the USA) ... however, the problem is that you need to enter the trial BEFORE your first brain tumor surgery.  Most people do not hear about this until after it is too late  We need to spread word of options such as these.  My pet peeve is that most neurosurgeons will not discuss the fact that by doing the surgery you will be forever excluded from clinical trials that require you to join before the first surgery.   Something to think about if you are about to have that first surgery.



10/11/12 IBTA E NEWS OCTOBER 2012        

 This is the monthly newsletter from our friends at the International Brain Tumor Association.



10/10/12 The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.        

 Interesting article.  It says that the addition of Temodar at the same time (and after) as radiation (which is now the standard of care) does NOT change the pattern of recurrence.  Most (91%) had recurrence in the same area as the original tumor which is about the same as when they used Temodar only after radiation.  The significance is this may mean widening the area radiated won't make much difference.



10/10/12 Impact of extent of resection for recurrent glioblastoma on overall survival.        

 This articles says that at the second surgery for a GBM, getting a complete resection adds a few months to survival.  We already knew that was true for the initial surgery. This might not sound like much, but it may be enough added time for something else to work.



10/10/12 Bevacizumab (Avastin) continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.        

 Although better than the alternatives tested,  still not good enough and shows the huge need for more research.  They didn't include the Novocure NovoTTF-100A which is the only other approved treatment for recurrent GBMs and they did not include any of the exciting clinical trials.



10/10/12 Effects of Zeng Sheng Ping/ACAPHA on malignant brain tumor growth and Notch signaling.        

  This is the way alternative treatments need to be tested - starting in the lab. I am sure many alternative treatments have an effect. We need to find the ones that help, and find the best ways to use them - this moves them from the "alternative" realm to the "mainstream" realm!



Displaying Stories 2550 to 2569 of 7806
Previous 20           Next 20